TCT 2023 The LIFE-BTK Trial

This was a randomized study including 261 patients treated with infrapatellar percutaneous transluminal angioplasty.173 of these patients received an everolimus bioresorbable scaffold while the remaining 88 were treated with balloon angioplasty. 

TCT 2023 | SWEDEHEART, evolución  a 5 años

The efficacy primary end point was limb salvage and primary patency rates at 12 months and the safety primary end point was freedom from major adverse limb events (MALE) and 30-day mortality. 

At 12 months, both the safety and the efficacy end points favored PCI with resorbable scaffold, with rates of 74.2% vs 47.9% (p < 0.0001) and 74.8% vs 49.4% (p < 0.001), respectively. Also, restenosis rate was significantly lower in the bioresorbable scaffold group (24.2% vs 46.5%, p < 0.0001), as was the combination of amputation, total occlusion and TLR (82.5% vs 70.4%).

In sum, the study authors concluded that the use of bioresorbable scaffolds is safe and effective, and is associated with lower incidence of restenosis, total occlusion and TLR.

Dr. Carlos Fava - Consejo Editorial SOLACI

Dr. Carlos Fava.
Member of the Editorial Board of SOLACI.org.

Presented by Ramon L. Varcoe during TCT 2023.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

New Carotid PCI All-in-One System

Carotid stenting is equivalent to carotid endarterectomy in terms of major adverse events (death, AMI, and stroke). However, it entails higher risk of minor...

PERFORMANCE II Trial: Safety and Efficacy of the New NeuroGuard Carotid Stent System

The percutaneous treatment of carotid artery disease through stenting (CAS) for the prevention of cerebrovascular disease has proven to be an effective alternative compared...

Trends in the Treatment of Critical Lower Limb Ischemia

Approximately 25% of patients with critical lower limb ischemia (CLLI) face amputation within the first year after diagnosis (according to statistics from the United...

Endovascular Treatment of Iliofemoral Disease for the Improvement of Heart Failure with Preserved Ejection Fraction

Peripheral artery disease (PAD) is a significant risk factor in the development of difficult-to-treat conditions, such as heart failure with preserved ejection fraction (HFpEF)....

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

Unplanned Coronary Angiography After TAVR: Incidence, Predictors, and Outcomes

The importance of assessing coronary artery disease in patients undergoing transcatheter aortic valve replacement (TAVR) is well recognized due to the high prevalence of...

Intravascular Lithotripsy in Calcified Coronary Lesions: Success Predictors

Coronary artery calcification (CAC) is increasingly common in patients undergoing percutaneous coronary intervention (PCI). Intravascular lithotripsy (IVL) has been established as an effective tool...

TAVR Unload: TAVR in Moderate Aortic Stenosis and Ventricular Function Deterioration

Aortic Stenosis (AS) significantly contributes to valvulo-arterial impedance in patients with heart failure and reduced ejection fraction (HFrEF), making it a relevant therapeutic target...